Cargando…
Combination therapy in cholesterol reduction: focus on ezetimibe and statins
Although widely used in lipid lowering therapy, HMG CoA reductase inhibitors (even when administered at high doses) are frequently insufficient to achieve guideline-recommended LDL-C goals for many patients with hypercholesterolemia in everyday clinical practice. Many patients do not achieve LDL-C g...
Autores principales: | Grigore, Liliana, Norata, Giuseppe Danilo, Catapano, Alberico L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496970/ https://www.ncbi.nlm.nih.gov/pubmed/18561502 |
Ejemplares similares
-
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010) -
Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease
por: Baragetti, Andrea, et al.
Publicado: (2020) -
Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014) -
High density lipoproteins and atherosclerosis: emerging aspects
por: Sala, Federica, et al.
Publicado: (2012) -
Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)